SIRNA THERAPEUTICS GRANTED BROAD PATENT COVERING RNAI-MEDIATED INHIBITION OF GENE EXPRESSION

Sirna Therapeutics, Inc. (Nasdaq: RNAI -- News) the leading clinical-stage RNAi therapeutics company, announced today that the United Kingdom Patent Office has issued a broad patent covering RNA interference (RNAi) mediated inhibition of gene expression using short-interfering ribonucleic acids (siRNA). The patent claims, which are not limited to a specific siRNA sequence or structure, broadly cover any siRNA molecule which targets conserved sequences within a virus or a gene. This patent is important because it enables increased therapeutic potential of RNAi technology.

Yahoo News (http://biz.yahoo.com/prnews/050927/latu077.html?.v=23)